RADIATION THERAPY ONCOLOGY GROUP
放射治疗肿瘤学组
基本信息
- 批准号:3556599
- 负责人:
- 金额:$ 3.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1979
- 资助国家:美国
- 起止时间:1979-02-01 至 1989-06-30
- 项目状态:已结题
- 来源:
- 关键词:brain neoplasms cervix neoplasms combination cancer therapy cooperative study head /neck neoplasm health care personnel human subject human therapy evaluation linear energy transfer lung neoplasms neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy neoplasm /cancer radiation therapy neoplasm /cancer thermotherapy radiation immunosuppression radiation protection radiation sensitivity radiobiology radiosensitizer
项目摘要
The support requested in this application is for the ongoing participation
of the Department of Radiation Oncology of the University of California,
San Francisco, and its affiliate institutions (the University of
California, San Diego; the University of California, Irvine; and Fresno
Community Hosptial of the UCSF Fresno campus) in the activities of the
Radiation Therapy Oncology Group (RTOG). The Department of Radiation
Oncology at UCSF is comprised of facilities at four institutions, that of
Moffitt - Long Hospital, Mt. Zion Hospital, Franklin Hospital, and the
Lawrence Berkeley Laboratory, together treating 2,700 new patients per
year. UCSF has participated in the RTOG since 1972 and are entering
approximately 150 patients per year into various group Phase I/II/III
protocols. Faculty members of the Department of Radiation Oncology at UCSF
have served under various committees and provided scientific input into
many of the RTOG protocols especially in the areas of radiosensitizers,
radioprotectors, isotopic immunotherapy, head and neck, CNS, and GYN tumors
and brain and liver metastases. Dr. Theodore L. Philips, the Associate
Principal Investigator and the Vice-chairman of the RTOG Modality Committee
was instrumental in the introduction of the radiosensitizer Misonidazole
into clinical use in the United States. The Department of Radiation
Oncology at UCSF was the primary institution wherein a number of Phase I/II
radiosensitizers protocols were carried out. Support through this
application will allow continued RTOG participation by the Department of
Radiation Oncology at UCSF and its affiliate institutions with the goal of
accessing 150-175 patients per year into various RTOG Protocols. Extensive
research into hyperthermia, chemical modification of radiation effects, and
radioimmunotherapy is expected to lead to innovative protocol development
within the group with a corresponding increase in the accession of patients
into studies sponsored by the RTOG.
此申请中要求的支持是针对正在进行的参与
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Evaluation of the bioavailability of misonidazole (NSC#261037) in capsule and tablet form and pharmacologic effects of daily dosage.
米索硝唑的生物利用度评价(NSC
- DOI:10.1016/0360-3016(82)90528-4
- 发表时间:1982
- 期刊:
- 影响因子:0
- 作者:VanRaalte,G;Phillips,TL;Wasserman,TH
- 通讯作者:Wasserman,TH
Promise of radiosensitizers and radioprotectors in the treatment of human cancer.
放射增敏剂和放射防护剂在治疗人类癌症中的前景。
- DOI:
- 发表时间:1984
- 期刊:
- 影响因子:0
- 作者:Phillips,TL;Wasserman,TH
- 通讯作者:Wasserman,TH
Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
缺氧细胞放射增敏剂米索硝唑美国 I 期临床试验最终报告(Ro-07-0582;NSC)
- DOI:10.1002/1097-0142(19811015)48:8<1697::aid-cncr2820480802>3.0.co;2-w
- 发表时间:1981
- 期刊:
- 影响因子:6.2
- 作者:Phillips,TL;Wasserman,TH;Johnson,RJ;Levin,VA;VanRaalte,G
- 通讯作者:VanRaalte,G
Clinical trials of hypoxic cell sensitizers.
缺氧细胞敏化剂的临床试验。
- DOI:10.1016/0360-3016(82)90633-2
- 发表时间:1982
- 期刊:
- 影响因子:0
- 作者:Phillips,TL;Wasserman,TH;Stetz,J;Brady,LW
- 通讯作者:Brady,LW
Palliation of liver metastases with combined hepatic irradiation and misonidazole. Results of a Radiation Therapy Oncology Group Phase I-II study.
联合肝照射和米索硝唑缓解肝转移。
- DOI:
- 发表时间:1981
- 期刊:
- 影响因子:0
- 作者:Leibel,SA;Order,SE;Rominger,CJ;Asbell,SO
- 通讯作者:Asbell,SO
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Theodore Phillips其他文献
Theodore Phillips的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Theodore Phillips', 18)}}的其他基金
RESEARCH BASE FOR SAN JOAQUIN VALLEY COMMUNITY CLINICAL
圣华金谷社区临床研究基地
- 批准号:
3558157 - 财政年份:1983
- 资助金额:
$ 3.61万 - 项目类别:
RESEARCH BASE FOR SAN JOAQUIN VALLEY COMMUNITY CLINICAL
圣华金谷社区临床研究基地
- 批准号:
3558158 - 财政年份:1983
- 资助金额:
$ 3.61万 - 项目类别:
NORTHERN CALIFORNIA CANCER PROGRAM CCOP RESEARCH BASE
北加州癌症计划 CCOP 研究基地
- 批准号:
3558156 - 财政年份:1983
- 资助金额:
$ 3.61万 - 项目类别:
NORTHERN CALIFORNIA CANCER PROGRAM CCOP RESEARCH BASE
北加州癌症计划 CCOP 研究基地
- 批准号:
3558159 - 财政年份:1983
- 资助金额:
$ 3.61万 - 项目类别: